Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.56 |
| ▸ | GRK6 | P43250 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | HK1 | P19367 | 1/20 | 0.44 |
| ▸ | HK2 | P52789 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870544 | 0.84 | ADK (0.53) | ADKGRK6CA1CA2HK1 | |
| SCHEMBL4874032 | 0.82 | GRK6 (0.52) | ADKGRK6CA1CA2TSHR | |
| SCHEMBL4900475 | 0.81 | GRK6 (0.56) | ADKGRK6CA1CA2TSHR | |
| SCHEMBL9399690 | 0.77 | CA1 (0.64) | ADKGRK6CA1CA2TSHR | |
| SCHEMBL14353232 | 0.77 | CA1 (0.64) | ADKGRK6CA1CA2TSHR | |
| SCHEMBL14478532 | 0.77 | GRK6 (0.55) | ADKGRK6CA1CA2HK1 | |
| SCHEMBL14478587 | 0.77 | CA1 (0.64) | ADKGRK6CA1CA2TSHR | |
| SCHEMBL14353191 | 0.77 | GRK6 (0.55) | ADKGRK6CA1CA2HK1 | |
| SCHEMBL15955793 | 0.77 | NPC1 (0.49) | ADKCA1CA2TSHR | |
| SCHEMBL4875722 | 0.77 | NPC1 (0.49) | ADKCA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | ADK 198/4885GRK6 3642/4885CA1 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.